Business Description
NanoViricides Inc. is a clinical-stage biopharmaceutical company based in Shelton, Connecticut, focused on developing treatments for a wide range of viral infections. Its leading drug candidate, NV-387, is being explored in multiple forms ? including oral syrups, gummies, injections, and inhaled solutions ? to treat respiratory illnesses such as RSV, influenza, and COVID-19, with several formulations currently in human clinical trials. The company is also working on treatments for conditions like shingles, cold sores, genital ulcers, HIV, Dengue, and Ebola. Founded in 2005, NanoViricides builds its pipeline on a proprietary nanoparticle platform designed to target and neutralize viruses in the body.
